InfuSystem vs IRadimed
INFU and IRMD side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How INFU and IRMD compare
IRadimed is the larger company, worth 3.7 times as much as InfuSystem ($1.1B against $293M).
On earnings, InfuSystem is cheaper: it trades at 32.7× trailing earnings, against 45.6× for IRadimed.
IRadimed grew revenue faster over the last twelve months (11.0% versus 2.4% for InfuSystem).
IRadimed keeps more of each dollar of sales as profit, with a net margin of 26.8% compared with 6.5% at InfuSystem.
IRadimed pays a dividend yielding 1.1%; InfuSystem does not pay one.
IRadimed scores higher on the StockData Score (19 against 15 for InfuSystem), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | INFU | IRMD |
|---|---|---|
| Size and price | ||
| Market cap | $293M | $1.1B |
| Share price | $14.72 | $85.35 |
| Change, 1 year | 41.1% | −1.2% |
| Change, 5 years | −17.6% | 119% |
| Beta (5Y) | 1.18 | 0.75 |
| Employees | 473 | 166 |
| StockData Score | ||
| Total score | 15 | 19 (better) |
| Valuation score | 3 (better) | 0 |
| Growth score | 2 | 4 (better) |
| Performance score | 4 | 6 (better) |
| Health score | 6 | 6 |
| Dividend score | 0 | 3 (better) |
| Valuation | ||
| P/E | 32.7× (better) | 45.6× |
| P/S | 2.0× (better) | 12.2× |
| P/B | 4.6× (better) | 10.3× |
| EV/EBITDA | 11.2× (better) | 33.7× |
| P/FCF | 11.8× (better) | 41.8× |
| PEG | – | 2.32 |
| FCF yield | 8.4% (better) | 2.4% |
| Fair value | $15.28 | $53.46 |
| Margin of safety | 3.7% (better) | −59.7% |
| Growth | ||
| Revenue growth (TTM) | 2.4% | 11.0% (better) |
| Revenue growth, 5Y average | 8.1% | 21.5% (better) |
| Net income growth (TTM) | 70.9% (better) | 13.2% |
| EPS growth (TTM) | 73.1% (better) | 13.3% |
| EPS growth, 5Y average | −17.3% | 73.9% (better) |
| Profitability | ||
| Gross margin | 57.6% | 75.5% (better) |
| Operating margin | 9.8% | 32.3% (better) |
| Net margin | 6.5% | 26.8% (better) |
| FCF margin | 17.1% | 29.3% (better) |
| Return on equity | 15.8% | 23.4% (better) |
| Return on invested capital | 13.4% | 52.3% (better) |
| Financial health | ||
| Debt / equity | 0.31 (better) | 0.00 |
| Net debt / EBITDA | 0.39 | – |
| Interest coverage | 13.8× | – |
| Current ratio | 2.68 | 8.99 (better) |
| Altman Z-score | 5.75 | 48.00 (better) |
| Piotroski F-score | 8 (better) | 6 |
| Dividends and buybacks | ||
| Dividend yield | – | 1.1% |
| Payout ratio | – | 67.6% |
| Buyback yield | 2.1% | – |
| Shareholder yield | 2.1% (better) | 1.1% |
| Ownership | ||
| Held by institutions | 79.1% | 61.4% |
| Held by insiders | 12.2% | 35.5% |
| Insider net buying, 12 months | $150K (better) | −$16.0M |
| Short interest, % of float | 3.9% | 7.2% |
Go deeper
- INFU stock overview
- INFU income statement
- INFU valuation and score
- IRMD stock overview
- IRMD income statement
- IRMD valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.